Replies to post #158236 on Biotech Values

[piggerpig]

xoma used very light doses for acne can you compare
The gout doses used by the other IL-1 drugs to this dose?

[north40000]

Why use either Accutane or Ilaris for acne with the AEs history?

I would try STSI's neutraceutical-based Anatabloc Skin Cream. Anatabine is synthesized S- isomer of a racemic mixture found in tobacco leaf, cucumber and other members of the solanacae family.
Seems harmless so far--I had an incipient cold sore on my lower lip
that disappeared in a day or 2 with application of one drop of the skin cream before going to bed. The cold sore never enlarged or broke open as they usually do. Anatabine is an anti-inflammatory.

Just a thought.

BTW, Anatabloc itself[unflavored version] has virtually removed the tinnitus in my ears which I had for many years after my 1st and last rock band concert. I think from past PMs with Biomaven that he may have tried Anatabloc also, but it did not work for him as far as tinnitus is concerned.

[DewDiligence]

XOMA—If the IL-1 drugs were rejected in gout (where both had very strong efficacy) then I don't think it likely that using them in acne (or, by extension, another IL-1 drug) is likely to get approval. Hence my puzzlement over even trying in that indication.

Your argument overlooks dosing differences between the various IL-1 drugs and the various trials! As piggerpig noted in #msg-85635600, the Gevokicumab trial in acne used low doses, which were weight-based; the higher of the two doses tested was 0.6mg/kg, which equates to a fixed dose of 45mg on average for the patients in that trial arm. This is 1/3 less than the 60mg dose being tested in EYEGUARD-B (for Behçet’s uveitis).

If the acne program advances to phase-3, XOMA may seek to use a fixed dose rather than a weight-based dose; if so, the fixed dose will likely be less than 60mg.

p.s. XOMA has not yet committed to advancing the acne program to phase-3.